143328-23-8

Basic information

• Product Name: 1-(3-BROMOPHENYL)CYCLOPENTANECARBOXYLIC ACID
• Synonyms: 1-(3-BROMOPHENYL)CYCLOPENTANECARBOXYLIC ACID;OTAVA-BB 1287312;CYCLOPENTANECARBOXYLIC ACID, 1-(3-BROMOPHENYL)-;1-(3-bromophenyl)cyclopentane-1-carboxylic acid
• CAS NO: 143328-23-8
• Molecular Formula: C₁₂H₁₃BrO₂
• Molecular Weight: 269.13
• Mol File: 143328-23-8.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(3-BROMOPHENYL)CYCLOPENTANECARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-BROMOPHENYL)CYCLOPENTANECARBOXYLIC ACID(143328-23-8)
• EPA Substance Registry System: 1-(3-BROMOPHENYL)CYCLOPENTANECARBOXYLIC ACID(143328-23-8)

Safety Data

• Hazardous Substances Data: 143328-23-8(Hazardous Substances Data)

Usage

Description

1-(3-BROMOPHENYL)CYCLOPENTANECARBOXYLIC ACID is a chemical compound with the molecular formula C12H13BrO2. It is a cyclopentanecarboxylic acid derivative with a bromine substitution on the phenyl ring. 1-(3-BROMOPHENYL)CYCLOPENTANECARBOXYLIC ACID is primarily used as a building block in organic synthesis and pharmaceutical research. It may also have potential applications in medicinal chemistry for the development of new drugs. As a carboxylic acid, it has the potential to form salts and esters and can participate in various chemical reactions. Overall, 1-(3-Bromophenyl)cyclopentanecarboxylic acid is an important intermediate for the preparation of various organic compounds and has potential applications in pharmaceutical and chemical industries.
Used in Pharmaceutical Industry:
1-(3-BROMOPHENYL)CYCLOPENTANECARBOXYLIC ACID is used as a building block for the synthesis of new drugs, contributing to the development of innovative pharmaceuticals.
Used in Chemical Industry:
1-(3-BROMOPHENYL)CYCLOPENTANECARBOXYLIC ACID is used as an important intermediate for the preparation of various organic compounds, facilitating the creation of a wide range of chemical products.

Upstream product

• 14062-30-7 ethyl 2-(3-bromophenyl)acetate 
• 1878-67-7 3-Bromophenylacetic acid 
• 885068-62-2 1-(3-bromo-phenyl)-cyclopentanecarboxylic acid ethyl ester 
• 31938-07-5 (3-bromophenyl)acetonitrile 
• 143328-18-1 1-(3-bromophenyl)cyclopentane-1-carbonitrile 

Downstream Products

• 1016644-54-4 3-(1-carboxy-cyclopentyl)-phenylboronic acid 
• 143433-71-0 Sodium; (6R,7R)-3-acetoxymethyl-7-{[1-(3-bromo-phenyl)-cyclopentanecarbonyl]-amino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylate 
• 143407-74-3 Sodium; (6R,7R)-7-{[1-(3-bromo-phenyl)-cyclopentanecarbonyl]-amino}-3-methyl-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylate 
• 143407-70-9 Sodium; (2S,5R,6R)-6-{[1-(3-bromo-phenyl)-cyclopentanecarbonyl]-amino}-3,3-dimethyl-7-oxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylate 
• 143328-28-3 1-(3-Bromo-phenyl)-cyclopentanecarbonyl chloride 

Relevant articles and documents

NEW BICYCLIC DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES

The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

2, 6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIDIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS

The present invention is directed a compound of Formula (I) as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, discorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).